Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus
Mala Dharmalingam, P Ganavi Yamasandhi
Indian Journal of Endocrinology and Metabolism (2018) Vol. 22, Iss. 3, pp. 421-421
Open Access | Times Cited: 196

Showing 1-25 of 196 citing articles:

Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial
Hua Cai, Yuelan Qin, Zeya Shi, et al.
BMC Gastroenterology (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 161
The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease
Sylwia Ziółkowska, Agata Binienda, Maciej Jabłkowski, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11128-11128
Open Access | Times Cited: 113
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Michelle Yi, L Cisneros, E.J. Cho, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 821-821
Open Access | Times Cited: 16
Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease
Julia M. Fraile, Soumya Palliyil, Caroline J. Barelle, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3997-4009
Open Access | Times Cited: 96
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, et al.
Cureus (2022)
Open Access | Times Cited: 39
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies
Muthukumaran Jayachandran, Shen Qu
Reviews in Endocrine and Metabolic Disorders (2023) Vol. 24, Iss. 6, pp. 1189-1204
Closed Access | Times Cited: 27
The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review
Azin Vakilpour, Ehsan Amini‐Salehi, Arman Soltani Moghadam, et al.
Nutrition and Diabetes (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications
Yu‐Ming Cheng, Chia‐Chi Wang, Jia‐Horng Kao
Hepatology International (2022) Vol. 17, Iss. 2, pp. 350-356
Open Access | Times Cited: 28
AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review
Rimesh Pal, Sanjay Kumar Bhadada
Bone (2023) Vol. 176, pp. 116884-116884
Closed Access | Times Cited: 17
Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
Gary Huang, Daniel F. Wallace, Elizabeth E. Powell, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2809-2809
Open Access | Times Cited: 17
Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
Mareca Lodge, Rachel Dykes, Arion Kennedy
Biomolecules (2024) Vol. 14, Iss. 7, pp. 845-845
Open Access | Times Cited: 6
Non-alcoholic fatty liver disease and LV diastolic dysfunction in patients with type 2 diabetes mellitus.
Maryam Faramarzpour, Mohammadreza Mohammad Hosseiniazar, Laya Hooshmand Gharabagh
PubMed (2025) Vol. 16, Iss. 1, pp. 47-57
Closed Access
PPARγ mediated enhanced lipid biogenesis fuels Mycobacterium tuberculosis growth in a drug-tolerant hepatocyte environment
Binayak Sarkar, Jyotsna Singh, Mohit Yadav, et al.
(2025)
Open Access
PPARγ mediated enhanced lipid biogenesis fuels Mycobacterium tuberculosis growth in a drug-tolerant hepatocyte environment
Binayak Sarkar, Jyotsna Singh, Mohit Yadav, et al.
(2025)
Open Access
Spending Money, Saving Money We Don’t Got: The Cost of Obesity
James A. Stone, Ana Johnson
Canadian Journal of Cardiology (2025) Vol. 41, Iss. 1, pp. 137-140
Closed Access
Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease
Justine Vily‐Petit, Maud Soty‐Roca, Marine Silva, et al.
Gut (2020) Vol. 69, Iss. 12, pp. 2193-2202
Closed Access | Times Cited: 45
Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice
Bing Li, Yu Cheng, Songyan Yu, et al.
Stem Cells International (2019) Vol. 2019, pp. 1-12
Open Access | Times Cited: 44
Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review
Adeboye Olakunle Bamgboye, Isaac Oluwadamilare Oni, Andrew Collier
European Journal of Clinical Pharmacology (2020) Vol. 77, Iss. 5, pp. 651-657
Closed Access | Times Cited: 39
Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity
Lucy I. Darakjian, Malavika Deodhar, Jacques Turgeon, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4967-4967
Open Access | Times Cited: 38
The role of platelets in non-alcoholic fatty liver disease: From pathophysiology to therapeutics
Navya Malladi, Md Jahangir Alam, Subir Kumar Maulik, et al.
Prostaglandins & Other Lipid Mediators (2023) Vol. 169, pp. 106766-106766
Closed Access | Times Cited: 14
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice
Ysabel C. Ilagan‐Ying, Bubu A. Banini, Albert Do, et al.
Current Gastroenterology Reports (2023) Vol. 25, Iss. 10, pp. 213-224
Closed Access | Times Cited: 14
Chlorogenic Acid Modulates Autophagy by Inhibiting the Activity of ALKBH5 Demethylase, Thereby Ameliorating Hepatic Steatosis
Fantong Meng, Chengchuang Song, Jia Liu, et al.
Journal of Agricultural and Food Chemistry (2023) Vol. 71, Iss. 41, pp. 15073-15086
Closed Access | Times Cited: 13
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients
Young-Hwan Park, Minji Sohn, So Yeon Lee, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 2, pp. 253-264
Open Access | Times Cited: 4
Early life interventions metformin and trodusquemine metabolically reprogram the developing mouse liver through transcriptomic alterations
Sarah Ashiqueali, Augusto Schneider, Xiang Zhu, et al.
Aging Cell (2024) Vol. 23, Iss. 9
Open Access | Times Cited: 4
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study
Shaowen Wang, C. H. Wang, Yu‐Ming Cheng, et al.
Hepatology International (2025)
Open Access
Page 1 - Next Page

Scroll to top